Daiwa Capital Markets Adjusts HUTCHMED Target Price to HK$26, Citing Consistent Annual Performance

Stock News

Mar 06

Daiwa Capital Markets issued a research report indicating that HUTCHMED (00013) is expected to receive approval for a new wave of drugs in the coming years due to smooth progress in research and development. The firm maintained a "Buy" rating but lowered the target price from HK$32.5 to HK$26, reflecting increased geopolitical risks. HUTCHMED's 2025 financial results were in line with expectations. Although total revenue declined by 13% year-on-year, sales of Fruquintinib showed a significant rebound following its launch, supported by continued growth in overseas markets and positive effects from sales restructuring in China. The company aims to achieve revenue between $330 million and $450 million in the oncology/immunology segment, benefiting from ongoing sales recovery.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1171651993"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171651993\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171651993?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171651993","market":"sh","top_or_hot":-1,"title":"Daiwa Capital Markets Adjusts HUTCHMED Target Price to HK$26, Citing Consistent Annual Performance","media":"Stock News","content":"<p>Daiwa Capital Markets issued a research report indicating that HUTCHMED (00013) is expected to receive approval for a new wave of drugs in the coming years due to smooth progress in research and development. The firm maintained a \"Buy\" rating but lowered the target price from HK$32.5 to HK$26, reflecting increased geopolitical risks. HUTCHMED's 2025 financial results were in line with expectations. Although total revenue declined by 13% year-on-year, sales of Fruquintinib showed a significant rebound following its launch, supported by continued growth in overseas markets and positive effects from sales restructuring in China. The company aims to achieve revenue between $330 million and $450 million in the oncology/immunology segment, benefiting from ongoing sales recovery.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Daiwa Capital Markets Adjusts HUTCHMED Target Price to HK$26, Citing Consistent Annual Performance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaiwa Capital Markets Adjusts HUTCHMED Target Price to HK$26, Citing Consistent Annual Performance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-06 14:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Daiwa Capital Markets issued a research report indicating that HUTCHMED (00013) is expected to receive approval for a new wave of drugs in the coming years due to smooth progress in research and development. The firm maintained a \"Buy\" rating but lowered the target price from HK$32.5 to HK$26, reflecting increased geopolitical risks. HUTCHMED's 2025 financial results were in line with expectations. Although total revenue declined by 13% year-on-year, sales of Fruquintinib showed a significant rebound following its launch, supported by continued growth in overseas markets and positive effects from sales restructuring in China. The company aims to achieve revenue between $330 million and $450 million in the oncology/immunology segment, benefiting from ongoing sales recovery.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1171651993","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171651993","pubTimestamp":1772777053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Daiwa Capital Markets issued a research report indicating that HUTCHMED (00013) is expected to receive approval for a new wave of drugs in the coming years due to smooth progress in research and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HCM":"和黄医药","BK4531":"中概回港概念","BK4588":"碎股","00013":"和黄医药","BK4585":"ETF&股票定投概念","BK1191":"制药","BK1587":"次新股","BK1588":"回港中概股"},"translate_title":"大和资本市场将和黄医药目标价调整至26港元，称全年表现一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"Daiwa Capital Markets issued a research report indicating that HUTCHMED (00013) is expected to receive approval for a new wave of drugs in the coming years due to smooth progress in research and development. The firm maintained a \"Buy\" rating but lowered the target price from HK$32.5 to HK$26, reflecting increased geopolitical risks. HUTCHMED's 2025 financial results were in line with expectations. Although total revenue declined by 13% year-on-year, sales of Fruquintinib showed a significant rebound following its launch, supported by continued growth in overseas markets and positive effects from sales restructuring in China. The company aims to achieve revenue between $330 million and $450 million in the oncology/immunology segment, benefiting from ongoing sales recovery.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}